Choose Language
Select a language for news translation.
Astellas Pharma's net income rose to 141.81 billion yen in Q1, up from 68.42 billion yen last year, reflecting strong demand and operational efficiencies. For …
Merck reported a $1.34 billion net loss in Q2 2023, prompting a cut in profit guidance due to $14.7 billion in acquisition-related charges, despite raising its…
Written by Eric Volkman for The Motley Fool -> The two companies will carry the Supernus name. Supernus also published its latest quarterly earnings release.…
Written by Brendan Coffey for The Motley Fool -> 20,000 shares were purchased for a total value of ~$1.1 million across multiple execution windows. The acqui…
On Friday, Ionis Pharmaceuticals' Director, Michael R. Hayden, made a $1.06M buy of IONS, purchasing 20,000 shares at a cost of $52.94 a piece. Ionis Pharmaceu…
The VanEck Pharmaceutical ETF (PPH) fell 1.8% on Monday, driven by a 7.2% drop in AstraZeneca and a 4.6% decline in Axsome Therapeutics. This downturn reflects…
Tilray Brands achieved an 11% revenue increase for fiscal 2026, primarily due to a 21% growth in its distribution business, which generated over $327 million. …
Japanese pharmaceutical giant Eisai reported a significant surge in first-quarter earnings, with net income attributable to parent company owners climbing 26% …
Written by Keith Noonan for The Motley Fool -> Teva posted its Q2 results this week, reporting an earnings miss even though sales beat expectations. The comp…
Written by Andy Gould for The Motley Fool -> The Health Care Select Sector SPDR Fund (XLV) carries a significantly lower expense ratio than the iShares U.S. P…
(RTTNews) - Regeneron Pharmaceuticals Inc (REGN) revealed a profit for second quarter that Drops, from the same period last year The company's earnings totale…
